Hyaluronic acid compared with corticosteroid injections for the treatment of osteoarthritis of the knee: a randomized control trial

Alireza Askari¹, Tahereh Gholami², Mohammad Mehdi NaghiZadeh³, Mojtaba Farjam⁴, Seyed Amin Kouhpayeh⁵* and Zahra Shahabfard⁶

Abstract

Background: Osteoarthritis (OA) is the most common chronic condition of the joints that takes place when the cartilage or a low friction surface between joints breaks down which leads to pain, stiffness and swelling. The purpose of the present study was to evaluate the therapeutic effect of intra-articular hyaluronic acid (HA) in comparison to corticosteroids (CS) for knee osteoarthritis.

Methods: 140 patients with knee osteoarthritis, who were followed for 3 months, were randomized to receive intra-articular injection of either hyaluronic acid or corticosteroid. By receiving one injection of drug during the enrollment in the study, the patients were treated. With the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Knee injury and Osteoarthritis Outcome Score (KOOS), and the visual analog pain scale, an independent, blinded evaluator assessed the patients three times.

Results: The mean age of the patients in the corticosteroid group were 57 ± 1.9 years and in Hyaluronic acid group were 58.5 ± 8.3 years. WOMAC score represented that pain and stiffness did not improve in neither groups at any time points after intervention (P > 0.05). KOOS score suggested that symptoms improved after 3 months in both CS and HA groups. Besides, daily activity improved in both groups (P < 0.05).

Conclusions: As a conclusion, it is argued that the most important difference between the two intervention groups is the duration of effectiveness. HA is suggested to be superior in the duration of pain relief when compared to CS. We can propose that HA can be administered every 3 months intra-articular for knee joint OA. Therefore, when CS has to be injected every 2 months, it will be more convenient to use HA.

Keywords: Osteoarthritis, Intra-articular injection, Hyaluronic acid, Corticosteroids, Pain, Stiffness, Iran

Background

Osteoarthritis is a chronic progressive joint disease which often affects middle-age to the elderly (Lawrence et al. 2008). A recent finding showed that symptomatic knee OA occurs in 10 % of men and 13 % of women aged 60 years or older (Zhang and Jordan 2010). The research demonstrated that multifactorial etiology such as a variety of risk factors including aging, genetics, trauma, mal alignment, and obesity interact with one another to cause the mentioned disorder (Loeser 2001). Pain reduction, joint mobility improvement, and functional impairment limitation are the major objectives in OA treatment. Moreover, regarding the maintenance of patients’ independence and quality of life, secondary goals have been taken into account for the reduction of disease progression and improvement of muscular strength (Snibbe and Gambardella 2005). There are various conservative
treatments for knee OA which provide short-term effectiveness with their own advantages and disadvantages (McArthur et al. 2012). By using a variety of non-surgical treatments, such as oral analgesics, non-steroidal anti-inflammatory drugs, or any of several types of intra-articular injections, for most patients it might prolong time to undergo surgery. This would be true if there could be any disease-modifying medication. This is why hyaluronic acid (HA) and corticosteroids (CS) are of particular interest.

Not merely intra-articular HA injections have a beneficial effect in the treatment of OA but also has some integral roles in improving joint lubrication, synovial fluid viscosity, normalizing hyaluronan synthesis, inhibiting proteoglycan degradation, exhibiting analgesic and anti-inflammatory effects (Day et al. 2004). Additionally, it has a long duration of action (Dixon et al. 1988; Dougados et al. 1993).

In recent decades, intra-articular injections of CS have been used in the treatment of OA but clinical evidences suggest short-term effectiveness, usually one to 4 weeks. Long-term treatment could promote joint destruction and tissue atrophy (Raynauld et al. 2003). Studies of cartilage damage, however, tend to recommend that changes are more likely due to the underlying disease than the steroid injection (Ayral 2001). Several clinical studies have been compared face to face HA and CS in knee OA (Leighton et al. 2014; Shimizu et al. 2010; Skwara et al. 2009). Colen et al. (2010), in meta-analysis study compared HA and CS and provided an efficacy pattern which had been changed by the passage of time and came into this conclusion that 8 weeks after injection, HA had greater efficacy. Numerous systematic reviews have investigated HA effects and other placebos (Colen et al. 2012; Divine et al. 2007), or CS and placebos (Arroll and Goodyear-Smith 2004; Godwin and Dawes 2004), however, there are a number of studies about HA and CS (Bannuru et al. 2009). Thus, the aim of the present study was to determine which treatment method was more effective to compare intra-articular HA injection with CS.

Methods
Design
This was a randomized, double blind study with parallel groups. After approval of institutional research deputy and ethics committee, the patient suffering from knee OA were randomized to receive IA injections of 2 cc of high molecular weight (500,000–730,000) HA (Fidia Farmaceutici S.p.A, Italy) or IA injections of 40 mg CS. The treatment consisted of one IA injections of HA or one injection of CS. And the follow-up visits were scheduled at 1, 2, and 3 months. Before inclusion, for fulfillment of the entry criteria, patients were evaluated. Moreover, qualified patients were informed about the aim and design of the study.

Adequate patients were randomized 1:1. A computer-generated list of random numbers was used. The random sequence was created through the freely accessible tools available at http://www.randomization.com, which uses the pseudo-random number generator of Wichmann and Hill (1982) modified by (McLeod 1985). This method helps to introduce several aim of interventions which includes a basis for the generator of random number which allows reproduction of the randomization model of one study when details and labels are assigned similarly.

At the initial visit the allocation sequence was hidden from the people in order to determine the patient’s eligibility. When the patients’ eligibility was confirmed by a physician, a number was presented. According to the randomization list, a physician was responsible for the patients’ assignment. Both the researcher in charge of evaluations at follow-up and patients’ group assignment and the patients were blind. By inserting the needle into the suprapatellar pouch, under aseptic conditions, administration of the IA treatments occurred using a single injection, planned to be repeated at 3 months. To avoid any effusions, before each injection, Arthrocentesis was performed.

Patients selection criteria
Qualified patients included men and women from 45 to 80 years who were suffering from knee OA for at least 3 months, along with radiographic OA grade II–III (According to Kellgren and Lawrence (KL) grading scale (Kellegant and Lawrence 1957), who signed the informed agreement form for participation). Main excluded participants for this study included a history or presence of trauma or surgery or cancer or malignant tumors, infections and sores on the target knee, history of vasovagal shock, use of NSAIDs in 2 days prior to injection, any receiving corticosteroids injection in the knee in the last 6 months, pregnancy and lactation.

Instruments
Western Ontario McMaster University Osteoarthritis (WOMAC)
In this study, Farsi version of the WOMAC index was used (Nadrian et al. 2012). The index is a 24-item questionnaire divided into three subscales which measure pain (5 items, score range 0–20), stiffness (2 items, score range 0–8), and physical function (17 items, score range 0–68). The three normalized subscale values were summed to provide the normalized WOMAC-total score. In the last section of follow-up, the researcher asked the WOMAC questions again.
The Knee Injury and Osteoarthritis Outcome Score (KOOS)
Having designed to evaluate the patients’ attitude on the knees and related problems, the KOOS is a tool specifically used for knee. The KOOS measures not only short-term but long-term sequellae of knee injury. It contains 42 items in 5 scored subscales including Pain, Other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and Knee-related Quality of Life (QOL) (Roos and Lohmander 2003).

Visual analog scale
The visual analog scale (VAS) is an instrument regularly used to measure pain intensity based on a 0–10 cm (Flan-dry et al. 1991). In the present study, the researcher asked the patients: “Based on VAS, how much pain are you in/experiencing?” In the follow-up sections, based on VAS, the researcher asks about their pain again. The measurement was recorded by the orthopedic surgeon.

Statistical analysis
Data was presented as mean ± standard deviation. Comparison of demographic variables were done with Chi square test. VAS pain, WOMAC and KOOS sub scores was evaluated during time and simultaneously compared between study groups with repeated measurement of ANOVA. All statistical analysis were done in IBM SPSS 19 (SPSS Inc, Chicago, IL). P value < 0.05 considered as significant level.

Results
In this study 69 patients at corticosteroid group with age of 57.0 ± 9.1 years and 71 in Hylan group with 58.5 ± 8.3 years were participated (P = 0.322). In corticosteroid group 17.4 % and in Hylan group 12.7 % were male (P = 0.435). Table 1 presented other characteristics of the groups. Two groups were at same marital (P = 0.984), education (P = 0.984) and occupation status (P = 708), and cigarette smoking (P = 0.984). All 140 recruited patients complete the 3 months follow-up.

Pain (VAS)
As shown in Fig. 1, before intervention pain score in corticosteroid group was 7.15 ± 2.01 same as Hylan group 7.52 ± 2.17 (P = 0.313). In corticosteroid group, pain at end of first month significantly decreased to 5.69 ± 2.33 (P < 0.001). At the end of second month, pain increased to 5.90 ± 2.33 but it was significantly lower than pain before intervention (P < 0.001). At end of third month, pain score increased to 6.56 ± 2.15 and it was not statistically different with primary pain (P = 0.200). In Hylan group at end of first month, pain significantly decreased to 6.63 ± 2.03 (P < 0.001). Unlike corticosteroid, at end of second month, pain continued its decreasing to 6.43 ± 2.01 (P < 0.001). At end of third month, pain score increased to 6.70 ± 2.01 but it was also significantly lower than primary pain (P = 0.020). The difference of pain between two groups was significant at end of first month (P = 0.018), but it was not significant at the end of second (P = 00.167) and third month (P = 0.720).

WOMAC score
Pain (P = 0.093) and stiffness (P = 0.712) in corticos-troid group along with pain (P = 0.109) and stiffness (P = 0.112) in Hylan group were not statistically different before 3 months after intervention (Table 2). On the con-trary, physical function problem significantly improved in both corticosteroid (P = 0.026) and Hylan (P = 0.043) groups.

KOOS score
Symptoms improved after 3 months in both corticosteroid (P = 0.010) and Hylan groups (P = 0.003). Besides, daily activity improved in both corticosteroid (P = 0.026) and Hylan groups (P = 0.046). On the contrary, pain did not decrease 3 months after intervention in both corticosteroid (P = 0.099) and Hylan groups (P = 0.170).

Discussion
Osteoarthritis is a chronic disabling disease with mor-bidity and pain. Knee is a weight bearing joint frequently affected by degenerative processes which cause much
disabilities. There are a few diseases modifying medical therapies for this disease condition. While primary treatment goals in knee OA include pain reduction improvement and improvement of joint mobility and function. Decreasing the progression of disease is an important secondary goal. Recent meta-analysis studies have argued that pharmacological interventions, to treat knee OA with oral NSAIDS, is inferior to intra-articular injections (Bannuru et al. 2015). Intra-articular injection of visco-supplementation with hyaluronic acid (HA) is a conservative intervention which is frequently administered with the hope of achievement of both primary and secondary therapeutic goals (Strand et al 2015).

Corticosteroids are other medications used as non-expensive pain modifying intra-articular injections (Bel-lamy et al. 2006), but there are no definite long-term benefits (Ray 2013). These two categories of intra-articular injections need to be clinically evaluated comparatively to assign their indications, contra-indications, cost-benefits and hence, to find their solid location in the algorithmic approach to the treatment of OA. Few studies have compared HA and CS (Bannuru et al. 2009). This can enrich the data regarding the use of non-surgical approaches to repair degenerated knee joints (Tiku and Sabaawy 2015). Thus, the aim of the present study was to determine which treatment method was more effective to pain alleviation and durability.

By using VAS, it was shown that both medications were equally effective in pain reduction in time points of first and second month after intervention. The effectiveness of pain reduction was more durable in HA group compared to CS. This was like what previous studies also provide (Ray 2013). At the end of the third month, pain score increased after decreasing at first and second month endpoints. At this point the score was not

Table 2 Comparison of WOMAC and KOOS Between Study Groups

|                      | Corticosteroid (n = 69) | Hylan (n = 71) | P value | ANOVA |
|----------------------|-------------------------|----------------|---------|-------|
|                      | Mean ± SD               | Mean ± SD      |         |       |
| WOMAC scores         |                         |                |         |       |
| Pain before (0–20)   | 13.21 ± 3.56            | 13.90 ± 4.37   | 0.332   |       |
| Pain after (0–20)    | 12.60 ± 3.69            | 13.11 ± 4.24   | 0.471   |       |
| Stiffness before (0–8)| 4.35 ± 2.69        | 4.71 ± 2.90   | 0.475   |       |
| Stiffness after (0–8)| 4.44 ± 2.63            | 4.29 ± 2.88   | 0.762   |       |
| Physical function before (0–68) | 35.98 ± 11.36 | 35.90 ± 12.38 | 0.970   |       |
| Physical function after (0–68) | 33.29 ± 11.03 | 33.54 ± 12.69 | 0.907   |       |
| KOOS scores          |                         |                |         |       |
| Pain before (0–100)  | 34.99 ± 17.93           | 31.48 ± 21.82  | 0.328   |       |
| Pain after (0–100)   | 37.95 ± 19.19           | 34.74 ± 21.61  | 0.383   |       |
| Symptoms before (0–100) | 39.23 ± 19.15   | 37.40 ± 20.07  | 0.784   |       |
| Symptoms after (0–100) | 43.78 ± 17.34 | 46.20 ± 20.16  | 0.473   |       |
| Daily activities before (0–100) | 47.08 ± 16.71 | 47.20 ± 18.20  | 0.970   |       |
| Daily activities after (0–100) | 51.04 ± 16.21 | 50.67 ± 18.67  | 0.867   |       |

Fig. 1 Comparison of pain trend in study groups
statistically different with the primary pain prior to intervention. It could be concluded that the duration of pain relief effectiveness is less than 3 months. On the contrary, the pain score remained significantly low after 3 months. In other words, the durability of efficacy of HA is more than 3 months and significantly longer compared to CS. Our result confirm the findings of Leighton et al., who reported the more durable effectiveness of HA compared to methylprednisolone (Leighton et al. 2014).

WOMAC score represented that pain and stiffness did not improve in neither groups at any time points after intervention (Table 2). However, physical function significantly improved in both groups. To our knowledge, this invaluable index has not been widely used in studies related to intra-articular injections (Vincent et al. 2013). However, this index is very appropriate in comparing the two injection methods. Besides, using KOOS score suggested that symptoms improved after 3 months in both corticosteroid and Hylan groups. Moreover, daily activity improved in both groups. This scoring system has provided a good clue to compare the clinical efficacy of each intervention (Peer and Lane 2013, van Meel et al. 2013).

Consequently, it is argued that the most important difference between the two interventions is the duration of effectiveness. Having compared to CS, HA is suggested to be superior in the duration of pain relief. We can propose that HA can be administered every 3 months intra-articular for knee joint OA. Therefore, it will be more convenient to use HA, when CS has to be injected every 2 months. It is probable that HA might be more cost-effective than CS although independent pharmaco-economic studies are not sufficient. Our results present a more conservative treatment plan compared to the results of Abate et al. (2015), who have suggested a 4 months interval schedule for intra-articular injection of HA, while we have clearly shown that a 3 months schedule is superior. In other studies, gender-related difference has been reported for the effect of HA. We did not find this difference (Leopold et al. 2003).

The superiority of our study on others is its double blind method. Furthermore, we did not focus only on pain score. This study has used several scales to clarify any differences between the two intra-articular injections. Future studies with more extensive follow-ups are demanding and will be taken into account by our research group.

Authors’ contributions
All authors have participated in this study as follow: AA participated in conception, design and carried out the injection, TG participated in data acquisition, MN participated in the design of the study and performed the statistical analysis, MF involved in drafting the manuscript, ZS participated in data acquisition and patient education. SK participated in conception, design and coordinated in manuscript drafting. All authors read and approved the final manuscript.

Author details
1 Department of Orthopedics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 2 School of Public Health, Fasa University of Medical Sciences, Fasa, Iran. 3 Department of Community Medicine and Statistics, Fasa University of Medical Sciences, Fasa, Iran. 4 Non-communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. 5 Department of Pharmacology, Fasa University of Medical Science, Fasa, Iran. 6 School of Nursing, Shiraz University of Medical Sciences, Shiraz, Iran.

Acknowledgements
This study is funded by Fasa University of Medical Sciences.

Competing interests
The authors declare that they have no competing interests.

Ethical approval
This study has approved as being an ethical research by the criteria of ethics in clinical trials. The code number of ethics committee is IRCT2015031421460N1.

Received: 8 November 2015 Accepted: 16 March 2016
Published online: 12 April 2016

References
Abate M, Vanni D, Pantalone A, Salini V (2015) Hyaluronic acid in knee osteoarthritis: preliminary results using a four months administration schedule. J Rheum Dis. doi:10.1111/1756-185X.12572
Arroll B, Goodyear-Smith F (2004) Corticosteroid injections for osteoarthritis of the knee: a meta-analysis. BMJ 328(7444):869
Ayral X (2001) Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 15(4):609–626
Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE (2009) Therapeutic trajectory of hyaluronic acid and corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthr Care Res 61(12):1704–1711
Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE (2015) Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 162(1):46–54
Bellamy N, Campbell J, Welch V, Goo TL, Bourne R, Wills GA (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Datab Syst Rev (2):CD005321. doi:10.1002/14651858.CD005321.pub2
Colen S, van den Bekerom MP, Bellemans J, Mulier M (2010) Comparison of intra-articular injections of Hyaluronic Acid and Corticosteroid in the treatment of Osteoarthritis of the hip in comparison with intra-articular injections of Bupivacaine. Design of a prospective, randomized, controlled study with blinding of the patients and outcome assessors. BMC Musculoskelet Disord 11(1):264
Colen S, van den Bekerom MP, Mulier M, Havercamp D (2012) Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs 26:257–268
Day R, Brooks P, Conaghan PG, Petersen M (2004) A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol 31(4):775–782
Divine JG, Zazulak BT, Hewett TE (2007) Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res 455:113–122
Dixon ASJ, Jacoby RK, Berry H, Hamilton EBD (1988) Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 11(4):205–213
Dougdados M, Nguyen M, Listrat V, Amor B (1993) High molecular weight sodium hyaluronate (hylaehrin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthr Cartil 1(2):97–103
Flandry F, Hunt JP, Terry GC, Hughston JC (1991) Analysis of subjective knee complaints using visual analog scales. Am J Sports Med 19(2):112–118
Godwin M, Dawes M (2004) Intra-articular steroid injections for painful knees. Systematic review with meta-analysis. Can Fam Physician 50(2):241–248

Systematic review with meta-analysis. Can Fam Physician 50(2):241–248

Systematic review with meta-analysis. Can Fam Physician 50(2):241–248
Kellgren JH, Lawrence JS (1957) Radiological assessment of osteoarthritis. Ann Rheum Dis 16:494–501
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35
Leighton R, Åkermark C, Therrien R, Richardson JB, Andersson M, Todman MG, Arden NK, DUROLANE Study Group (2014) NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage 22(1):17–25
Leopold SS, Redd BB, Warme WJ, Wehrle PA, Pettis PD, Shott S (2003) Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. J Bone Joint Surg Am 85(7):1197–1203
Loeser RF (2001) Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin Geriatr Med 26:371–386
McArthur BA, Dy CJ, Fabricant PD, Della Valle AG (2012) Long term safety, efficacy, and patient acceptability of hyaluronic acid injection in patients with painful osteoarthritis of the knee. Patient Prefer Adher 6:905
McLeod Al (1985) Remark AS R58: a remark on algorithm AS 183. An efficient and portable pseudo-random number generator. Appl Stat 34:198–200
Nadrian H, Moghimi N, Nadrian E, Moradzadeh R, Rahmanpour K, Iranpour A, Bellamy N (2012) Validity and reliability of the Persian versions of WOMAC Osteoarthritis Index and Lequesne Algofunctional Index. Clin Rheumatol 31 (7):1097–1102
Peir MA, Lane J (2013) The Knee Injury and Osteoarthritis Outcome Score (KOOS): a review of its psychometric properties in people undergoing total knee arthroplasty. J Orthop Sports Phys Ther 43(1):20–28
Ray TR (2013) Using viscosupplementation to treat knee osteoarthritis. Physician Sportsmed 41(4):16–24
Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Harauzi B, Martin-Pelle-tier J, Uthman L, Khy V, Tremblay JL, Bertrand C, Pelletier JP (2003) Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 48(2):370–377
Roos EM, Lohmander LS (2003) The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes 1(1):64
Shimizu M, Higuchi H, Takagishi K, Shinozaki T, Kobayashi T (2010) Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. J Orthop Sci 15(1):51–56
Skwara A, Ponelis R, Tibešku CO, Rosenbaum D, Fuchs-Winkelmann S (2009) Gait patterns after intraarticular treatment of patients with osteoarthritis of the knee-hyaluronan versus triamcinolone: a prospective, randomized, doubleblind, monocentric study. Eur J Med Res 14(4):157
Snibbe JC, Gambardella RA (2005) Treatment options for osteoarthritis. Orthopedics 28(2):S215
Strand V, McIntyre LF, Beach WR, Miller LE, Block JE (2015) Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res 8:217
Tiku ML, Sabaawy HE (2015) Cartilage regeneration for treatment of osteoarthritis: a paradigm for nonsurgical intervention. Ther Adv Musculoskelet Dis 7(3):76–87
van Meer BL, Meuffels DE, Vissers MM, Bierma-Zeinstra SM, Verhaar JA, Terwee CB, Reijman M (2013) Knee injury and Osteoarthritis Outcome Score or International Knee Documentation Committee Subjective Knee Form: which questionnaire is most useful to monitor patients with an anterior cruciate ligament rupture in the short term? Arthrosc J Arthrosc Relat Surg 29(4):701–715
Vincent HK, Percival SS, Conrad BP, Seay AN, Montero C, Vincent KR (2013) Hyaluronic acid (HA) viscosupplementation on synovial fluid inflammation in knee osteoarthritis: a pilot study. Open Orthop J 7:378
Wichmann BA, Hill ID (1982) Algorithm AS 183: an efficient and portable pseudo-random number generator. Appl Stat 31:188–190
Zhang Y, Jordan JM (2010) Epidemiology of osteoarthritis. Clin Geriatr Med 26(3):355–369